The results reported here indicate that retinoic acid (RA) induces growth arrest and dierentiation only in MyoDexpressing muscle cells. Transient transfection assays reveal a functional interaction between MyoD, a key myogenic regulator and RA-receptors, principal mediators of RA actions. Interestingly, we demonstrate that RXR-MyoD-containing complexes are recruited at speci®c MyoD DNA-binding sites in muscle cells.
Introduction
Retinoic acid (RA), a natural derivative of vitamin A, regulates the growth and dierentiation of a wide variety of cell types (De Luca, 1991; Chambon, 1994; Gudas et al., 1994; Hofmann and Eichele, 1994) . These actions are mediated by two families of ligandinducible transcriptional factors, the retinoic acid receptors (RARa, b and g) and the retinoid X receptors (RXRa, b and g) which are members of the nuclear receptor superfamily (Evans, 1988; Chambon, 1994; GigueÁ re, 1994; Gronemeyer and Laudet, 1995; Mangelsdorf and Evans, 1995) . RARs bind and are activated by all-trans RA and its 9-cis isomer (Zelent et al., 1989; Allenby et al., 1993) whereas RXRs bind and are activated by 9-cis RA only Levin et al., 1992; Mangelsdorf et al., 1992) . RARs and RXRs transregulate target gene expression by binding as heterodimers to speci®c RA response elements (RAREs). Furthermore, RXRs also serve as heterodimeric partners for other members of the nuclear receptor superfamily (GigueÁ re, 1994; Glass, 1994) . These combinatorial interactions result in a ®ne tuning of RA-receptor activity and could explain how RA elicits highly pleiotropic eects on the dierentiation of numerous cell types.
Dierentiation of skeletal muscle cells sequentially requires growth arrest followed by the onset of a timely ordered expression of muscle-speci®c genes. This programme depends on the myogenic regulatory proteins, including the basic helix ± loop ± helix (b-HLH) proteins MyoD, myogenin, Myf5, MRF4 Lassar and Munsterberg, 1994; Olson and Klein, 1994 ) and the MADS domain transcription factor MEF2 (Gossett et al., 1989; Yu et al., 1992; Olson et al., 1995) . The muscle-speci®c b-HLH factors dimerize with an ubiquitous class of b-HLH E-proteins for activation of muscle-speci®c genes (Murre et al., 1989; Lassar et al., 1991; Hu et al., 1992) . Furthermore, MyoD also associates with several non-b-HLH proteins to control withdrawal from cell cycle and induction of the myogenic phenotype (Bengal et al., 1992; Gu et al., 1993; Kaushal et al., 1994; Schneider et al., 1994; Eckner et al., 1996; Groisman et al., 1996; Molkentin et al., 1995; Puri et al., 1997) . Compelling evidence in the literature indicates that RA induces myogenesis of various muscle cells (Gabbert et al., 1988; Arnold et al., 1992; MomoõÈ et al., 1992; Albagli-Curiel et al., 1993; Halevy and Lerman, 1993) . In the case of C2 myoblasts, RA is an ecient inducer of both growth arrest and dierentiation (AlbagliCuriel et al., 1993) . These eects have been associated with an RA-induction of MyoD and myogenin gene expression. These observations suggest that RAreceptors and MyoD might act in the same regulatory pathway that governs the RA-induced myogenesis.
Here, we investigated the functional and biochemical relationships between RA-receptors and MyoD that in¯uence cell growth and dierentiation in muscle cells. Using various muscle cell lines which dier in their pattern of MyoD expression, we found that the promyogenic eect of RA is correlated with the presence of this muscle transcription factor. Consistent with these data we further show that RA-receptors and MyoD up-regulate each other's transcriptional activity. We establish that this coactivation involves a direct association of RA-receptors with myogenic b-HLH factors and propose that the interaction of RAreceptors and myogenic b-HLH proteins is important for the execution of RA-induced myogenic differentiation. The demonstration that the members of the nuclear receptor superfamily (RAR and RXR) and the MyoD family can physically interact establishes a mechanism for myogenic activation by retinoic acid.
Results

MyoD is required for mediating the RA signal in myogenesis
In C2 myoblasts, RA rapidly increases MyoD gene expression (Albagli-Curiel et al., 1993) suggesting a possible role of this myogenic factor in the mediation of RA-induced skeletal myogenesis. To test this possibility, we compared the eects of RA in mouse C2 and rat L6 myogenic cell lines which dier in MyoD gene expression (Braun et al., 1989; . Unlike C2 cells, L6 myoblasts do not express MyoD. We also investigated the RA sensitivity of C2 cells in which MyoD gene expression was inhibited and of L6 cells overexpressing MyoD. For this purpose, we used a previously-described C2 cell line which constitutively produces antisense MyoD RNA (referred to as C2AM for C2 Anti-MyoD) . Moreover, we established an L6 myogenic cell line stably transfected with a vector expressing sense MyoD RNA (referred to as L6M for L6 MyoD) (this work). Control (C2C and L6C) and transfected (C2AM and L6M) cells were tested for their MyoD gene expression. As expected, C2C and L6M cells express MyoD whereas C2AM and L6C cells do not express MyoD as determined by immuno¯uorescence analysis (Figure 1a) . We then examined these cell lines for their sensitivity to RA with respect to their proliferation and dierentiation properties.
RA-induced myogenic dierentiation in these cell lines was tested by immuno¯uorescence analysis. Myoblasts were induced to dierentiate in low serum medium ( Figure 1 ) supplemented with RA (10 76 M) for 4 days, then immunostained for troponin T, a late muscle marker. Cells expressing MyoD (C2C and L6M) depicted an increased staining for troponin T protein in response to RA (Figure 1a) . By contrast, cells in which MyoD is absent (C2AM and L6C) are largely insensitive to RA-induced dierentiation. The C2AM cell line failed to dierentiate when treated with RA. Note that, unlike C2AM cells, L6C myoblasts expressed the muscle-speci®c marker upon RA-treatment, but a similar dierentiation was also obtained in Table 1 ). Therefore, MyoD expression appeared to be required for myoblast dierentiation in the presence of RA. Changes in the RA responsiveness of these cell lines were further investigated by measuring cell growth in the presence and absence of RA. Cells were plated in a proliferative medium (Figure 1 ) and treated or not with 10 76 M RA, then proliferation was evaluated using [ 3 H]thymidine incorporation experiments. As shown in Figure 1b . RA strongly inhibited growth of myoblasts expressing MyoD (C2C and L6M). This inhibitory eect was detectable after 2 days and after 4 days reached about 90% relative to the value in non-treated cells. By contrast, RA did not signi®cantly prevent proliferation of the MyoD-defective cells (C2AM and L6C) (Figure 1b) . Therefore, RA-induced growth arrest is only observed in the myogenic cell lines expressing MyoD. In conclusion, these data establish that the RA-induced growth arrest and dierentiation in muscle cells are directly linked to the presence of MyoD.
RA-receptors and MyoD can co-operate in transcriptional activation
Sense or antisense MyoD RNA expression could induce changes in the expression and function of nuclear RA-receptors (RARs and RXRs) which are the major mediators of RA eects. Northern blots indicated that the pattern of RAR and RXR expression is independent of the presence or absence of MyoD in each of both L6 and C2 cell lines (data not shown). We then performed transfection experiments to test for a functional interaction between retinoid acid receptors and the MyoD factor. Reporter constructs containing a retinoic acid response element (TREpalX3-tk-CAT or RAREb-tk-CAT) were transiently cotransfected with or without plasmids expressing an RA-receptor (RARa or RXRa) and MyoD in mouse C3H10T1/2 ®broblasts (Figure 2a and b) . These cells do not express MyoD but are`permissive' for its functions (Davis et al., 1987) . In presence of RA, TREpalX3-tk-CAT activity was increased upon RARa or RXRa overexpression. Strikingly, a stronger (twoand fourfold more) ligand-dependent reporter activity was obtained when RARa or RXRa was cotransfected with MyoD. This stimulation of RA-induced CAT activity is MyoD dose-dependent (Figure 2a) . Analogous results were obtained with the RAREb-tk-CAT reporter gene (Figure 2b ). These results indicate that MyoD potentiates the transactivation of RA-receptors and support a role for MyoD as a positive cofactor in the retinoic acid receptor signalling pathway.
Reciprocally, we investigated whether RA-receptors could increase MyoD transcriptional activity. C3H10T1/2 cells were cotransfected with a reporter construct containing the E-box DNA-binding sites b Figure 1 RA-induced dierentiation and growth arrest in C2 and L6 myoblasts are linked to MyoD gene expression. The control C2 cells (C2C) and C2 anti-MyoD cells (C2AM) have previously been described . L6 cells (clone L6G7) (YaeÂ and Saxel, 1977) were cotransfected with 10 mg of pEMSV vectors containing or lacking the murine MyoD coding sequence (respectively designated L6C and L6M) and 500 ng of pSV2neo. The transfected L6 cells were selected for 2 weeks in proliferation medium (Dulbecco's modi®ed Eagle's medium (DMEM) (1 vol) / Ham F-12 (1 vol) supplemented with 10% Fetal Calf Serum (FCS)) with G418 (1 mg/ml). Individual colonies were isolated, then passaged into stable cell lines. (a) C2C, C2AM, L6C and L6M cells were induced to dierentiate in DMEM with 2% FCS and all-trans RA (10 76 M) for 4 days, then double-immunostained with troponin T monoclonal antibody (Sigma) and MyoD antiserum (Vandromme et al., 1995) 
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The percentages correspond to the ratio of the cells stained with an anti-troponin T antibody by immuno¯uorescence analysis versus the total number of nuclei stained with Hoechst. The percentages are determined after counting more than 10 3 cells for each point from the a-subunit promoter of mouse acetylcholine receptor (E-box-tkCAT), the expression vectors encoding MyoD and an RA-receptor (RARa or RXRa). In the absence of RA, MyoD overexpression activated the AchR-a subunit promoter (Olson and Klein, 1994; and Figure 2b) . In the presence of RA, this basal CAT transactivity was enhanced about twofold suggesting a functional implication of endogenous RA-receptors in C3H10T1/2 cells. A maximal RA-eect on MyoD activity was obtained when MyoD was coexpressed with one of the two RA-receptors (RARa or RXRa). Thus, MyoD appeared to be more ecient (about 2 ± 4-fold) in activating the E-box reporter gene in the presence of ligand-activated RA-receptors ( Figure 2b ). This RA-potentiation of MyoD activity was dependent on RA-receptor concentrations ( Figure 2b ) and required intact E-box DNA-binding sites in the AchR-a subunit promoter (data not shown). These data show that MyoD potentiates retinoid acid receptor activity in the induction of RA-responsive elements and reciprocally that RA-receptors stimulate the activation capacity of MyoD in the presence of RA.
RA-receptors are present in the protein complex formed on the speci®c MyoD DNA target sequences
To investigate whether RA-receptors and myogenic b-HLH proteins can be detected in a common protein complex, we performed electrophoretic mobility shift assay (EMSA) experiments using a 32 P-labelled single E-box oligomer speci®c for MyoD DNA binding (Bengal et al., 1994) . Nuclear extracts of undifferentiated C2 myoblasts and dierentiated C2 myotubes display E-box DNA-binding activities (two complexes marked myo/E, Figure 3 , lanes 1 and 7, solid arrows). The binding speci®city of these complexes was con®rmed by competition experiments with excess of unlabelled E-box-speci®c oligonucleotide (lanes 2 and 8). These complexes were speci®cally supershifted by a MyoD-speci®c antibody (lanes 4 and 10), and most likely represent heterodimeric complexes between myogenic and ubiquitous b-HLH proteins . Note that the MyoD antibody preferentially supershifts the high (*) and to a lesser extent the low (**) molecular weight myo/E complex, most likely because its epitope was not exposed. In addition, two dierent monoclonal antibodies directed against either RXR (a, b and g) or RXRa both supershifted these complexes (preferentially the low mobility myo/E complex **) (lanes 5, 6, 11 and 12), demonstrating the presence of RXRa in E-box DNA-binding activity. The speci®city of this supershift was con®rmed using either an unrelated monoclonal antibody (lanes 3 and 9) or by adding the antibodies to the probe directly in the absence of C2 cell extracts, which does not result in any supershifted band (data not shown). Similar results were observed using an oligonucleotide bearing two Eboxes (data not shown). From these results, we conclude that RXRa constitutes part of the speci®c E-box-bound complexes.
Interaction between RA-receptors and myogenic b-HLH proteins occurs through DNA-binding domains
To test whether or not RA-receptors can directly interact with MyoD, we then performed in vitro glutathione-S-transferase (GST) pull-down experiments. We ®rst examined the ability of GST fusion protein containing full-length MyoD (GST-MyoD) to speci®cally bind in vitro-translated full-length RARa and RXRa (Figure 4a , right panel). In both the presence or absence of RA, 35 S-methionin-labelled RXRa and RARa bound recombinant GST-MyoD with high eciency, but did not interact with the control GST protein. In the reverse experiments, RARa or RXRa-GST resins (GST-RXRa or GSTRARa) also retained speci®cally in vitro-translated MyoD (Figure 4a left panel) . These results con®rm that the two families of RA-receptors physically interact with MyoD transcriptional factor in an RAindependent manner. This interaction was not due to residual DNA since it was also observed in the presence of ethidium bromide, which prevents DNAdependent protein-protein interaction (data not shown).
The domains of each polypeptide required for this interaction were mapped by similar in vitro protein binding experiments (Figure 4b, c and d) . E12, myogenin, MyoD b-HLH proteins and various MyoD deletion mutants were translated in vitro and analysed for association with the GST-RXRa fusion protein (Figure 4b) . Interestingly, MyoD and myogenin, but not E12, eciently bound GST-RXRa indicating that RXRa interacts speci®cally with the myogenic subclass of b-HLH proteins (Figure 4b) . Among the MyoD mutants tested, internal deletion mutants encompassing the basic domain (amino acids 102 ± 114) and the basic®rst helix junction (amino acids 102 ± 135), failed to bind GST-RXRa. Similar results were obtained using GST-RARa resin (data not shown). Thus, the basic domain of muscle b-HLH factors is necessary for binding RA-receptors. Furthermore, these MyoD mutants which did not interact with RA-receptors failed to potentiate the transcriptional activity of RAreceptors (as measured by the TREpalX3-tk-CAT in C3H10T12 cell line) (Figure 5a ). To further analyse this association, RXRa, RXRb and various deletion mutants as well as other members of the steroid receptor superfamily (THRb thyroid hormone receptorb and ERa: estrogen receptor a) were radiolabelled in vitro and allowed to react with the GST-MyoD fusion protein (Figure 4c) . Interestingly, RXRa, RXRb and THRb, but not ERa bound GST-MyoD, suggesting that MyoD recognition could be restricted to a subset of nuclear hormonal receptors (see discussion). Among the RA-receptor mutants tested, only mutant RA-receptors containing an intact DNAbinding domain eciently interact with GST-MyoD (Figure 4c ). Similar results were obtained with RARa (data not shown). This suggests that RA-receptorMyoD interaction requires the DNA-binding domain of RA-receptors. Accordingly, the mutant GSTRXRaDABC which has the N-terminal A/B and the DBD regions deleted failed to interact with MyoD ( Figure 4d) . As a control, this mutant fusion protein was still capable of interacting with RARa ( Figure 4d ). As reported in Figure 5b , the DBD-deletion RAreceptor which did not interact with MyoD failed to potentiate the MyoD transcriptional activity (measured by the E-box-tkCAT in C3H10T1/2 cell line). In summary (Figure 5c ), our results establish that RAreceptors and the muscle b-HLH proteins physically interact through DNA-binding domains. In addition, the ability of RA-receptors and MyoD to upregulate each other's transcriptional activity correlates well with their abilities to interact physically, suggesting that this interaction is important for functional interactions between these two families of transcription factors.
Discussion
The data reported here present new evidence for functional cooperation between the two RA-receptor families and MyoD in the mediation of anti-proliferative and dierentiation eects of RA in muscle cells. We found that the promyogenic eect of RA diers in various muscle cell lines and is correlated with the presence of MyoD. Consistent with these data, we further show that RA-receptors and MyoD upregulate each other's transcriptional activity in the presence of RA: this cooperation requires physical interaction between myogenic factors and RA-receptors.
RA biological activities are dependent on MyoD gene expression
RA is known to cause a reduction of cell growth combined with dierentiation of many cell types (De Luca, 1991 Figure 3 RXRa localizes at E-box MyoD DNA-binding sites. Electrophoretic mobility shift assay using nuclear-cell extracts from C2 myoblasts (lanes 1 ± 6) and from dierentiated C2 myotubes (cultured for 48 h in low serum medium) (lanes 7 ± 12). A gel shift probe containing one E-box was employed. Lanes 1 and 7 show the gel shift pattern obtained with extract alone. In lanes 2 and 8, a 100-fold excess of cold E-box oligonucleotide was added to the gel shift reaction. For the other lanes, the antibodies indicated at the top were added to the binding reaction. A speci®c supershift was obtained with antibodies directed against the b-HLH MyoD protein (lanes 4 and 10), as well as with the 4RX-1D12 (directed against RXRa, b and g) and 4RX3A2 (directed against RXRa) monoclonal RXR antibodies (lanes 5, 11 and 6, 12 respectively) but not with a speci®c non-cross-reactive monoclonal antibody directed against CDK2 (noted ns: lanes 3 and 9). Complexes marked myo/E correspond to E-box DNAbinding activities. Two RXR antibodies (lanes 5, 6 and 11, 12) supershifted these complexes (marked RXRs + MyoD). Open arrows indicate complexes supershifted with MyoD antibody Hofmann and Eichele, 1994) . In cultured myoblasts, this RA-antiproliferative eect is necessary but not sucient to trigger myogenesis (FroeschleÂ et al., 1996) . Interestingly, MyoD also inhibits cell cycle progression independently of myogenic dierentiation (Crescenzi et al., 1990; Sorrentino et al., 1990) . Part of the mechanism by which MyoD and RA initiate and maintain the growth arrest stage of dierentiation might be explained by direct interaction of these two factors with several cell cycle regulatory proteins (Bengal et al., 1992;  input GST GST-RXRα GST-RARα Schneider et al., 1994; Groisman et al., 1996) . Here, we have shown that ligand-activated RA-receptors require the presence of MyoD to prevent proliferation in C2 and L6 myoblasts. This observation indicates that these two families of transcription factors cooperate in mediating the RA-antiproliferative eect which is a prerequisite for muscle terminal dierentiation.
MyoD
We previously observed that in C2 myoblasts, RA is able to enhance MyoD and myogenin gene expression (Albagli-Curiel et al., 1993) and thereby probably improves the autoregulation and interregulation loops of myogenic b-HLH factors, leading to increased amounts of muscle transcription factors that are required for activation of the myogenic programme (Thayer et al., 1989) . It is also possible that, besides enhancing expression of myogenic b-HLH factors, RA might also regulate their activity. This is strongly suggested by our previous ®nding that RA abrogates the transactivating function of the transcription factor AP1 (Albagli-Curiel et al., 1993) , an inhibitor of both myogenic factor expression and activity (Bengal et al., 1992; Li et al., 1992) . In addition, it has been shown that RA induces myogenin expression in a rhabdomyosarcoma cell line, probably by regulating MyoD activity (Arnold et al., 1992) . Here, we report that RAreceptors activate the endogenous myogenic programme only in MyoD-positive cells. This eect can be partly explained by the RA-potentiation of MyoD activity, and reciprocally, as demonstrated in transient transfection experiments. Thus, a functional interaction between RA-receptors and myogenic factors might be involved in both induction and maintenance of the myogenic phenotype.
Functional cooperation between RA-receptors and MyoD factors requires direct protein-protein interactions
The cooperation between RA-receptors and myogenic b-HLH proteins to mediate RA-responsive events in muscle cells suggests that these factors interact physically. Here, we report that these two regulatory protein families interact through the DNA-binding domain of RA-receptors and the basic domain of muscle factors comprising the myogenic function. We further show that MyoD recognition is restricted to class II of nuclear receptors as MyoD binds to RAR, RXR and THR, but not ER (a member of class I of nuclear receptors). Interestingly, RA-receptors do not interact with the ubiquitous E12 b-HLH protein. Thus, the muscle speci®city of this interaction results from the discrimination by RA-receptors between myogenic and non-myogenic b-HLH domains. Moreover, this speci®c interaction could underlie the RA eects on muscle cells. Indeed, we show that functional cooperation between RA-receptors and myogenic b-HLH proteins correlates with their abilities to interact with each other, suggesting the importance of the physical interaction between these two transcription factor families.
It is also possible that other factors mediate functional collaboration. The members of the myocyte-speci®c enhancer factor 2 (MEF2) family could be candidate molecules for such co-regulatory activities. MEF2 participates in the induction and maintenance of muscle-dierentiated phenotype by inducing the expression of, and directly associating with, the myogenic b-HLH proteins (Kaushal et al., 1994; Molkentin and Olson, 1996) . MEF2 has also been shown to interact with members of the nuclear receptor family, however it binds weakly to RAR and not at all to RXR (Lee et al., 1997) . Taken together with the ®nding that the degree of functional cooperation correlated well with that of protein-protein interaction, we propose that direct interactions between RAreceptors and MyoD are crucial for the mediation of RA eects in muscle cells.
Molecular mechanisms of myogenic coactivation by RA-receptors
Given that unliganded receptors are already involved in this direct protein-protein association and are part of the MyoD protein complex on the E-box, the speci®c action of RA might lie in its ability to stimulate the transcriptional activity of the complex RAreceptors/myogenic factors. Comparison of structures of unliganded with liganded RA-receptors (Bourguet et al., 1995; Renaud et al., 1995; Wurtz et al., 1996) suggests that RA-binding induces a conformational change allowing the receptors to interact with several putative transcriptional intermediary factors required for RA-dependent transcriptional activity Schulman et al., 1995; Swaeld et al., 1995; vom Baur et al., 1995; May et al., 1996) . Thus, through these positive cofactors/mediators, only the liganded-complex RA-receptors/myogenic factors might act eciently on the basal transcription machinery, as recently described for complexes involving nuclear receptors (Fondell et al., 1993; Lee et al., 1994; Valcarcel et al., 1994; Chakravarti et al., 1996) . Consistent with this view, p300/CBP have been reported acting as coactivators for RA-receptors but also for the transcriptional factor MyoD (Chakravarti et al., 1996; Eckner et al., 1996; Yuan et al., 1996; Puri et al., 1997; Sartorelli et al., 1997) . Because p300/CBP have histone acetyl transferase activity and thereby can contribute directly to transcriptional regulation (Ogryzko et al., 1996) , it is conceivable that the interaction of p300/CBP with the complex RAreceptors/MyoD may be important for integrating RA transcriptional-activation signals in muscle cells. Further studies are necessary to determine precisely how the RA-receptor/myogenic b-HLH factor interaction stimulates the basal transcriptional machinery. In conclusion, association between RA-receptors and myogenic b-HLH factors could explain the coordination and cross-coupling of RA-induced growth arrest and myogenic dierentiation. It is thus possible that speci®c actions of RA-receptors in a wide variety of cell types may derive from their interaction with cellspeci®c regulatory molecules.
Materials and methods
Cell culture products
Dulbecco's modi®ed Eagle's medium (DMEM), nutrient mixture F-12 (Ham) and Fetal Calf Serum (FCS) were purchased from Gibco-BRL. All-trans retinoic acid (RA) was obtained from Sigma. All-trans RA was diluted in dimethyl sulfoxide (DMSO).
Cell culture conditions
C3H10T1/2 ®broblasts were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) (Rezniko et al., 1973) . C2 (clone C2.7) and L6 (clone L6G7) myoblasts have been previously described (YaeÂ and Saxel, 1977) . All cultures were performed at 378C in a humidi®ed atmosphere of air with 5% CO 2 . Proliferating myoblasts were routinely maintained in growth medium (GM), a 1 : 1 mixture of Ham F-12/DMEM supplemented with 10% (vol/vol) Fetal Calf Serum (FCS) and subcultured twice a week. Before any treatment with all-trans RA, cells were grown for about 7 days in GM containing 10% hormone-depleted FCS. Depleted serum was obtained using the resin procedure of Samuels et al. (1979) . All RA treatments were performed at about 48 h after plating at a density of 2610 3 cells/cm 2 . For dierentiation, cells plated at a density of 4610 3 cells/ cm 2 were grown for 3 days in GM containing 10% hormone-depleted FCS then transferred into differentiation medium consisting of DMEM and 2% hormonedepleted FCS. The RA treatment was administered when the medium was changed. Control cells received solvent alone (0.1% DMSO).
Reporter expression vectors and other plasmids
The reporter constructs TREpalx3-tk-CAT, RAREb-tk-CAT have been previously described (FroeschleÂ et al., 1996) . The construct E-box-tk-CAT is referred to as paAChCAT+ (Piette et al., 1990) .
GST-RARa, GST-RXRa and GST-RXRaDABC, previously referred to as GSTRXRa(DE), in pGEM vector were described Schulman et al., 1995; Swaeld et al., 1995; vom Baur et al., 1995; May et al., 1996) . pSG5-RARa, pSG5-RXRa, pSG5-RXRaDAB and pSG5-RXRaDEF (previously referred to as pSG5-RXRadn) expression vectors have been described Nagpal et al., 1992) . The RXRbDC expression vector, pSG5-RXRbDC contains a RXRbcDNA lacking the DBD domain, referred to as pcxn2RXRbDBD 7 (Minucci et al., 1994) , which was cloned into pSG5 and controlled by sequence.
pEMSV-MyoD was a kind gift of Dr H. Weintraub (Davis et al., 1987) . MyoD mutants previously referred to as DM 63 ± 99, DM 102 ± 114, DM 102 ± 135, in pEMSV vector lack respectively the C/H domain, the basic domain, the basichelix1 region (Davis and Weintraub, 1992) . Additional proteins included RXRb (Zelent et al., 1989) , THRb (Weinberger et al., 1986) , ERa (Green et al., 1986) , myogenin (Schwarz et al., 1992) , E12 (Trouche et al., 1993) and GST-MyoD (Groisman et al., 1996) .
DNA transfections and CAT assays
Transfections and CAT assays were performed as described (FroeschleÂ et al., 1996) , except that C3H10T1/2 cells were transfected. Transfections of plasmid DNA were performed using DOTAP reagent (Boehringer) as described by the supplier. Brie¯y, cells were transfected with 1 mg of reporter constructs, 2 mg of b-galactosidase expression vector (PCH110-Pharmacia) and 2.25 mg of a mixture of vectors expressing MyoD, RARa or RXRa (Figures 2 and  5 ). Cells were exposed to the DNA for 8 h then refed with DMEM/HamF-12 medium supplemented with 10% depleted FCS. RA treatment (10 76 M) was performed 24 h after transfection.
Determination of CAT activity was performed as previously described (Pfahl et al., 1990) . The b-galactosidase activity was measured as previously described (Nilsen et al., 1983) to normalize for transfection eciency.
DNA-binding assays
Nuclear cell extracts of exponentially growing or differentiated C2 cells were prepared as follows. Cells were washed with ice-cold phosphate-buered saline (PBS) and resuspended in lysis buer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP40 detergent, 4 mM dithiothreitol (DTT), 10 mg of leupeptin per ml, 10 mg of aprotinin per ml). The cells were centrifugated at 48C, and the pellet was resuspended in nuclear buer (30 mM Tris pH 7.9, 350 mM NaCl, 5 mM DTT, 10% glycerol, 20 mM sodium¯uoride, 20 mM glycophosphate, 10 mg of leupeptin per ml, 10 mg of aprotinin per ml). After 30 min incubation on ice, cell nuclear extracts were clari®ed by centrifugation at 13 000 r.p.m. Nuclear extracts were combined in 20 ml of binding reaction buer containing 12.5 mM Tris pH 7.9, 50 mM KCl, 5 mM MgCl 2 , 7.5% glycerol, 0.1 mM DTT, 0.5 mg of poly(dI-dC) and 32 P-endlabelled E-box probe (5'-GATCCAGCAGGTGTGAAT-TCG-3'). After 15 min at room temperature, samples were subjected to electrophoresis in a 4% non-denaturing polyacrylamide gel. For competition experiments, 100-fold molar excess of unlabelled E-box oligonucleotide was added to the reaction mixture prior to addition of extract. For antibody shift EMSAs, concentrated antibodies were added to extracts at room temperature for 30 min before the DNA-binding reaction was started. The following antibodies were used: 5.8A MyoD monoclonal antibody (Dako), 4RX-1D12 (directed against RXRa, b and g) and 4RX3A2 (directed against RXRa) monoclonal RXR antibodies (Rochette-Egly et al., 1994) and M22 Cdk2 polyclonal antibody (Tebu) used as a control.
In vitro transcription-translation and GST-binding assays
One microgram of various supercoiled DNA plasmids was transcribed in vitro and then translated in the presence of [
35 S]methionine with the TnT-coupled reticulocyte lysate system (Promega) according to the manufacturer's suggestions. Expression and puri®cation of glutathione S-transferase (GST) fusion proteins were performed as described by Gu et al. (1993) .
To perform a protein-protein interaction assay, GST fusion proteins coupled to glutathione-agarose beads (Pharmacia) were incubated with various in vitro-translated proteins overnight at 48C in binding buer (20 mM HEPES (pH 7.9), 50 mM KCl, 2.5 mM MgCl 2 10% glycerol, 1 mM DTT). Then the glutathione beads were collected by brief centrifugation and washed ®ve times with RIPA buer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.2% Nonidet P-40 detergent, 1 mM PMSF). For each reaction tube, equal amounts of GST fusion proteins or in vitro-translated 35 S-Met-labelled proteins were used. The protein amounts were estimated to the band intensities by Coomassie blue staining or autoradiography (Radioactivity on the gels was determined on a PhosphorImager analyzer). Bound proteins were boiled in sodium dodecyl sulfate (SDS) loading buer, resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and detected by autoradiography.
